ABIONYX Pharma Provides an Update on Its Activity, Its Revenue and Its Cash Position for the Third Quarter of 2023
17 November 2023 - 4:00AM
Business Wire
- 5th patient with LCAT deficiency, also known as Norum
disease, to be treated under Compassionate Access in
Europe
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world's only recombinant human apoA-1, today provides an update on
its activity, its revenue and its cash position for the 3rd quarter
ended September 30, 2023.
The Company recorded consolidated revenue of €3,595 K for the
first nine months of the year, after elimination of intra-group
transactions. IRIS Pharma was the only company within the Group to
generate revenue as of September 30, 2023, as the activity
dedicated to the discovery and development of innovative therapies
to improve the lives of patients did not generate any revenue over
the first 9 months.
As of September 30, 2023, ABIONYX Pharma's cash position stood
at €1.7 million. This cash position does not include the €3 million
capital increase carried out by ABIONYX Pharma on October 6, 2023,
or the reimbursement of IRIS Pharma's French Tax Credit (CIR) in
the amount of €736 K, also in October 2023.
In September 2023, CER-001 vials were provided under
compassionate access for a new patient in Italy with the rare
kidney disease LCAT Deficiency which has no existing treatment.
This is the fifth patient suffering from LCAT deficiency, also
known as Norum disease, to be treated with CER-001 in Europe. The
five patients suffering from this rare disease, which has a major
impact on quality of life and on lifespan, represent very different
stages in the evolution of the disease for which CER-001 may prove
effective, whether the patients are transplanted or not, and
whatever their age and severity of symptoms. ABIONYX is continuing
its efforts to identify patients with this ultra-rare disease,
support their treating physicians in seeking necessary approvals in
their country/region, advising on appropriate treatment regimen to
use and follow-up assessments to be performed, and providing
CER-001 to them.
In the renal area, Phase 2 clinical data from the RACERS study
in sepsis was selected for a Late-Breaking Clinical Results Poster
presentation, at the American Society of Nephrology (ASN) Annual
Meeting, which took place November 2-5, 2023, in Philadelphia,
Pennsylvania. The full results of the RACERS study were published
simultaneously and exclusively in the journal BMC Medicine (Nature
Springer).
Two additional abstracts generated from ABIONYX-sponsored
research programs were also accepted by the ASN for presentation at
their 2023 Annual Meeting: an oral presentation on CER-001
treatment in ischemia reperfusion injury, and a poster on the
action of CER-001 in "Brain Fog" associated with acute kidney
injury. These preclinical results provide data that support
exploring potential additional indications for CER-001 in future
clinical studies.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new apoA-I vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231116202117/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Apr 2024 to May 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From May 2023 to May 2024